Issels Treatment Analysis
It has been argued, and I agree, that alternative, unconventional, and complementary cancer treatments occupy slots on a medical continuum that includes clinical trials and concludes with the mainstream. The content of mainstream medicine changes with time, and there is a tendency for the continuum to feed into the standardized treatment pool (eg, radiation was once considered unconventional and unpopular, but has long since achieved tenure in the mainstream). However, some treatments languish at the far end of the spectrum despite sufficient evidence to justify further disciplined inquiry. I refer to these as "orphaned treatments." Several of these treatments come to mind as I review the case demonstrated here.
This unfortunate 60-year-old woman is a heavy smoker with occupational exposure to solvents and paints. She has a 1-year history of nonproductive cough and weight loss. She is status post-right-upper lobectomy for a stage IIA poorly differentiated adenocarcinoma with 11 regional nodes involved.
The first and most essential part of treatment has been accomplished by the surgeon (i.e., the tumor and regional affected lymph nodes have been removed). Unfortunately, despite appropriate surgical management, fatal recurrences claim the substantial majority of properly debulked stage IIA lung adenocarcinoma patients. Worse, overall survival is not altered by adjuvant chemotherapy or radiotherapy.
Because survival is the only endpoint of concern here, I would recommend that we look to the orphaned treatments for ways to address this. From the perspective of published outcomes assessments (where one can find information about long-term survival), the most interesting alternative approach is that of Josef Issels who, at the time of his death in 1998, was referred to in the Los Angeles Times as the "father of integrative cancer treatment." Issels approached cancer as a multidisciplinary challenge, according to his hypothesis of the pathogenesis of cancer. 1 Issels was convinced that malignant neogenesis was the product of a preceding syndrome starting with multiple and chronic challenges, producing immediate as well as secondary damages to the host, resulting in the development of a premalignant milieu, and concluding with development of the malignancy. Therefore, in addition to the tumor, Issels focused on this set of problems, which he treated through elimination of chronic insults, correction of their damages, and restoration of the patient's overall physiological integrity. Although this viewpoint is not well known, it is justified by the outcomes. Two independent university-level epidemiological reviews, conducted more than a decade apart, confirmed that Issels's approach was in fact curing nearly 20% of a population of exhaustively pretreated cancer patients with advancing disease. 2, 3 Later outcomes assessments indicated that treatment prevented many recurrences. 1 Issels employed nonspecific desensitizing, pro-host management to promote tissue integrity, resistance, and immunity while at the same time debulking tumors and focal infections. In this context, he employed nonspecific bacterial reagents and specific active vaccines. The precepts of the Issels approach can be satisfied by the following orphaned treatments. 1 . Coley's toxins. Starnes 4 referred to this mixed bacterial vaccine as perhaps the most powerful single anticancer agent. There is a great deal of data to support this view, and current international interest is demonstrated by the involvement of universities 5, 6 and pharmaceutical firms 7 in pursuit of the potential seen in Coley's toxins. Regression and resolution of tumors has been documented in patients undergoing periodic fevers induced by the nonspecific challenge of Coley's toxins. This vaccine has been part of the Issels management for more than 50 years.
Issels's autologous vaccine. This vaccine, a key part of
Issels's therapy, 2 was developed during a lengthy collaboration with mycoplasma authority Franz Gerlach 8 and based on repeated experimental observation of mycoplasma-induced malignant conversion. It is an antigenic fraction of the patient's own mycoplasmas and similar organisms, affording specific immunization. Current research continues to bolster the impression of the importance of these organisms in cancer. 9 3. Gerson's cancer therapy. The evidence quietly continues to accumulate for Gerson's diet therapy 10 and subsequent close variants (Kelley, Gonzalez). 11 Seminal thoracic surgeon Ferdinand Sauerbruch was an outspoken advocate of the salt-restricted diet and its ability to enhance surgical wound healing and resistance/immunity to infection. 12 The majority of European investigators agreed that the diet therapy was curative against cutaneous tuberculosis. 13 It was demonstrated in a series of investigations at the University of Munich to induce sodium-losing diuresis effective against the infiltrative edema and effusions of established pulmonary tuberculosis, as well as other types of edema and fluid collection. Temporary protein restriction was shown to result in a left shift of the differential white blood cell count, a bandemia during neutrophil-mediated inflammation, and lymphocytosis at tubercular lesions, followed by lymphocyte infiltration of these lesions and their subsequent resolution. 14 In cancer, Gerson repeatedly noted arrest and regression of metastases and, less frequently, primaries under the influence of his combined regimen. 15 Gerson attempted to interest the post-World War II medical community of New York but was unsuccessful. However, Issels took note and eventually proposed using Gerson's therapy as part of his multidisciplinary approach (J. M. Issels, personal communication, July 1996). 4. Hyperbaric oxygen. Another modality notable for its ability to enhance wound healing and resistance/ immunity to infection is hyperbaric oxygen, a logical companion management. Little is understood about the actual mechanisms involved in the vast variety of beneficial physiological effects of hyperbaric oxygen. Yet, one after another, empirical applications of hyperbaric oxygen have slowly come into acceptance (eg, closed head injury, stroke, diabetic ulcers, refractory osteomyelitis). 16 Having made the case for treatments from the far end of the spectrum, I would hasten to add several approaches from the middle of the spectrum, including expressive arts therapy, counseling, visualization, and creative novation therapy.
This alternative approach is in no way less complicated than mainstream approaches. Both Coley's toxins and Gerson's therapy (capable of causing spiking fevers itself) should be regarded as aggressive interventions that require training in internal medicine and immunology, in addition to current knowledge of oncology.
Integrative Physician Notes
Medical Oncology Analysis Dr. Stolbach, demonstrating the gifts of a seasoned oncologist, has gone beyond the other practitioners in this Integrative Tumor Board in evaluating the medical aspects of this case, coming to the conclusion that this patient's prognosis is probably worse than that of most patients with stage IIA NSCLC. He has given co-gent support for this conclusion due to the extent of lymph node involvement, as well as the findings on the right adrenal gland. His recommendations for further testing that would be appropriate include several evaluations including MRI of the right adrenal mass, biopsy of this mass, and mediastinoscopy. These evaluations would help determine whether the staging assigned is accurate. The findings up to the date of writing lend credibility to the possibility that this patient has an aggressive cancer and more involvement than is evident on the evaluations already done. The suggestion that the patient may need chemotherapy at some point to delay the symptomatic phase of her disease is very reasonable in this light.
Naturopathic Medicine
Dr Fulop provides an interesting and unusual case analysis of this patient from the naturopathic viewpoint, as well as an excellent literature review on the relationship of diet and lung cancer. In her discussion of surgery, she mentions the necessity of using modified citrus pectin post-resection to prevent metastases. We too are impressed with the early literature on the potential role of citrus pectin in this context, and we feel this is a reasonable suggestion, although we question whether the literature yet supports viewing this agent as an actual necessity.
Fulop's discussion of smoking in this patient is quite fascinating. The literature certainly supports the benefits of smoking cessation for lung cancer patients. [1] [2] [3] The idea that long-term smoking results in a readaptation of a variety of biological systems, with a resulting homeostasis that will be disrupted when the smoker tries to stop, is an important thought to bear in mind. Fulop's suggestion that this patient only cease smoking if she is motivated to do so is in fact reasonable from a physiological and certainly a psychological viewpoint; one hopes that the diagnosis will in fact give her that motivation. The suggestion of support with acupuncture, herbs, and nutrients during the withdrawal process is excellent; mind-body techniques should also assist in the process. An effort should be made to discuss the potential benefits of smoking cessation after diagnosis of cancer with the patient so that she understands that, especially with her still limited extent of disease, she is not already doomed to disease progression and may actually avoid recurrence. Should she elect to receive chemotherapy, she should also receive counseling about the potential interaction of smoking with chemotherapy drugs and related medications: because smoking induces CYP450 3A4, it has the potential to lower blood levels of chemotherapy drugs that are metabolized by this phase I enzyme; paclitaxel, a common component of many treatment regimens for lung cancer, could be affected by this
